Podium to Practice: ASH® 2025 – MULTIPLE MYELOMA: Phase 1b of REDIRECTT-1: Results with an extended median follow-up of 3 years

Podium to Practice: ASH® 2025 – MULTIPLE MYELOMA: Phase 1b of REDIRECTT-1: Results with an extended median follow-up of 3 years

Podium to Practice: ASH® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Donna Reece

Icon Chair Speaker

Speakers

Dr. Darrell White

Dr. Maria Victoria Mateos Manteca

Studies / Trials Discussed

ID 701 – Safety and efficacy of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma from Phase 1b of redirectt-1: Results with an extended median follow-up of 3 years

Studies/trials discussed:

ID 701 – Safety and efficacy of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma from Phase 1b of redirectt-1: Results with an extended median follow-up of 3 years
Tagged